Cargando…

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in B...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranzani, Otavio T., Hitchings, Matt D. T., de Melo, Rosana Leite, de França, Giovanny V. A., Fernandes, Cássia de Fátima R., Lind, Margaret L., Torres, Mario Sergio Scaramuzzini, Tsuha, Daniel Henrique, David, Leticia C. S., Said, Rodrigo F. C., Almiron, Maria, de Oliveira, Roberto D., Cummings, Derek A. T., Dean, Natalie E., Andrews, Jason R., Ko, Albert I., Croda, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537178/
https://www.ncbi.nlm.nih.gov/pubmed/36202800
http://dx.doi.org/10.1038/s41467-022-33169-0
Descripción
Sumario:The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.